Market Closed -
Canadian Securities Exchange
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1800 CAD | 0.00% | -7.69% | -14.29% |
Dec. 31 | Innocan Pharma Closes Private Placement for $635,444 | MT |
Dec. 30 | InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding | CI |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | - | 8K | 196K | 2.56M | 13.66M | |
Total Revenues | - | 8K | 196K | 2.56M | 13.66M | |
Cost of Goods Sold, Total | - | 5K | 75K | 452K | 1.68M | |
Gross Profit | - | 3K | 121K | 2.11M | 11.98M | |
Selling General & Admin Expenses, Total | 2.63M | 2.98M | 6.2M | 6.85M | 13.98M | |
R&D Expenses | 368K | 1.74M | 1.4M | 1.53M | 1.8M | |
Other Operating Expenses, Total | 3M | 4.73M | 7.6M | 8.37M | 15.78M | |
Operating Income | -3M | -4.72M | -7.48M | -6.27M | -3.8M | |
Interest Expense, Total | -40K | - | -13K | -2K | - | |
Interest And Investment Income | - | 21K | - | - | - | |
Net Interest Expenses | -40K | 21K | -13K | -2K | - | |
Currency Exchange Gains (Loss) | - | - | -290K | -415K | 4K | |
Other Non Operating Income (Expenses) | -294K | -5.25M | -2.31M | 2.8M | -235K | |
EBT, Excl. Unusual Items | -3.34M | -9.95M | -10.09M | -3.89M | -4.03M | |
EBT, Incl. Unusual Items | -3.34M | -9.95M | -10.09M | -3.89M | -4.03M | |
Income Tax Expense | - | - | - | 1K | 214K | |
Earnings From Continuing Operations | -3.34M | -9.95M | -10.09M | -3.89M | -4.25M | |
Net Income to Company | -3.34M | -9.95M | -10.09M | -3.89M | -4.25M | |
Minority Interest | - | - | 44K | 125K | -452K | |
Net Income - (IS) | -3.34M | -9.95M | -10.05M | -3.76M | -4.7M | |
Net Income to Common Incl Extra Items | -3.34M | -9.95M | -10.05M | -3.76M | -4.7M | |
Net Income to Common Excl. Extra Items | -3.34M | -9.95M | -10.05M | -3.76M | -4.7M | |
Per Share Items | ||||||
Net EPS - Basic | -0.03 | -0.06 | -0.04 | -0.02 | -0.02 | |
Basic EPS - Continuing Operations | -0.03 | -0.06 | -0.04 | -0.02 | -0.02 | |
Basic Weighted Average Shares Outstanding | 121M | 162M | 225M | 249M | 257M | |
Net EPS - Diluted | -0.03 | -0.06 | -0.04 | -0.02 | -0.02 | |
Diluted EPS - Continuing Operations | -0.03 | -0.06 | -0.04 | -0.02 | -0.02 | |
Diluted Weighted Average Shares Outstanding | 121M | 162M | 225M | 249M | 257M | |
Normalized Basic EPS | -0.02 | -0.04 | -0.03 | -0.01 | -0.01 | |
Normalized Diluted EPS | -0.02 | -0.04 | -0.03 | -0.01 | -0.01 | |
Supplemental Items | ||||||
EBITDA | -3M | -4.68M | -7.44M | -6.23M | -3.77M | |
EBITA | -3M | -4.72M | -7.48M | -6.27M | -3.8M | |
EBIT | -3M | -4.72M | -7.48M | -6.27M | -3.8M | |
Effective Tax Rate - (Ratio) | - | - | - | -0.03 | -5.3 | |
Normalized Net Income | -2.08M | -6.22M | -6.26M | -2.3M | -2.97M | |
Interest on Long-Term Debt | 334K | - | - | - | - | |
Supplemental Operating Expense Items | ||||||
Selling and Marketing Expenses | 695K | 914K | 2.5M | 3.49M | 10.91M | |
General and Administrative Expenses | 1.94M | 2.07M | 3.71M | 3.36M | 3.08M | |
Research And Development Expense From Footnotes | 368K | 1.74M | 1.4M | 1.53M | 1.8M | |
Stock-Based Comp., R&D Exp. (Total) | 57K | 64K | 109K | 120K | 102K | |
Stock-Based Comp., S&M Exp. (Total) | 121K | 121K | 490K | 223K | 96K | |
Stock-Based Comp., G&A Exp. (Total) | 248K | 343K | 1.56M | 624K | 656K | |
Stock-Based Comp., Other (Total) | - | - | -1K | - | - | |
Total Stock-Based Compensation | 426K | 528K | 2.16M | 967K | 854K |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Assets | ||||||
Cash And Equivalents | 1.97M | 2.34M | 11.05M | 4.95M | 3.88M | |
Total Cash And Short Term Investments | 1.97M | 2.34M | 11.05M | 4.95M | 3.88M | |
Accounts Receivable, Total | - | 2K | - | 62K | 249K | |
Other Receivables | 57K | 1.13M | 169K | 181K | 445K | |
Total Receivables | 57K | 1.13M | 169K | 243K | 694K | |
Inventory | - | 430K | 510K | 1.13M | 1.75M | |
Prepaid Expenses | 426K | 309K | 715K | 453K | 340K | |
Other Current Assets, Total | 31K | 72K | 79K | 104K | 138K | |
Total Current Assets | 2.49M | 4.28M | 12.52M | 6.88M | 6.8M | |
Net Property Plant And Equipment | 95K | 56K | 54K | 98K | 136K | |
Total Assets | 2.58M | 4.33M | 12.58M | 6.98M | 6.94M | |
Liabilities | ||||||
Accounts Payable, Total | 27K | 527K | 53K | 95K | 112K | |
Accrued Expenses, Total | 409K | 384K | 432K | 318K | 463K | |
Current Portion of Leases | 34K | 37K | 1K | 14K | 22K | |
Other Current Liabilities | 661K | 6.99M | 3.08M | 304K | 1.95M | |
Total Current Liabilities | 1.13M | 7.94M | 3.56M | 731K | 2.54M | |
Long-Term Leases | 38K | 1K | - | 20K | 11K | |
Total Liabilities | 1.17M | 7.94M | 3.56M | 751K | 2.55M | |
Common Stock, Total | - | - | - | - | - | |
Additional Paid In Capital | 6.02M | 10.96M | 33.66M | 34.77M | 37.18M | |
Retained Earnings | -4.61M | -14.56M | -24.61M | -28.37M | -33.07M | |
Total Common Equity | 1.41M | -3.61M | 9.06M | 6.39M | 4.1M | |
Minority Interest | - | - | -44K | -169K | 283K | |
Total Equity | 1.41M | -3.61M | 9.01M | 6.22M | 4.39M | |
Total Liabilities And Equity | 2.58M | 4.33M | 12.58M | 6.98M | 6.94M | |
Supplemental Items | ||||||
ECS Total Shares Outstanding on Filing Date | 144M | 215M | 248M | 252M | 281M | |
ECS Total Common Shares Outstanding | 144M | 188M | 248M | 250M | 268M | |
Book Value / Share | 0.01 | -0.02 | 0.04 | 0.03 | 0.02 | |
Tangible Book Value | 1.41M | -3.61M | 9.06M | 6.39M | 4.1M | |
Tangible Book Value Per Share | 0.01 | -0.02 | 0.04 | 0.03 | 0.02 | |
Total Debt | 72K | 38K | 1K | 34K | 33K | |
Net Debt | -1.9M | -2.3M | -11.05M | -4.91M | -3.85M | |
Minority Interest, Total (Incl. Fin. Div) | - | - | -44K | -169K | 283K | |
Account Code - Inventory Valuation | 3 | - | 5 | 5 | 5 | |
Inventories - Raw Materials, Total | - | 203K | 188K | 224K | 214K | |
Inventories - Finished Goods, Total | - | 227K | 322K | 907K | 1.53M | |
Full Time Employees | - | - | - | - | - | |
Part Time Employees | - | - | - | - | - |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Income | -3.34M | -9.95M | -10.05M | -3.76M | -4.7M | |
Depreciation & Amortization - CF | 23K | 40K | 43K | 35K | 33K | |
Depreciation & Amortization, Total | 23K | 40K | 43K | 35K | 33K | |
Stock-Based Compensation (CF) | 426K | 527K | 2.16M | 967K | 854K | |
Other Operating Activities, Total | 298K | 5.22M | 2.18M | -2.77M | 702K | |
Change In Accounts Receivable | -63K | -2K | 2K | -15K | -2K | |
Change In Inventories | - | -430K | -79K | -621K | -616K | |
Change In Accounts Payable | 27K | 500K | -474K | 42K | 17K | |
Change in Other Net Operating Assets | -91K | 406K | -418K | 63K | -192K | |
Cash from Operations | -2.72M | -3.69M | -6.63M | -6.07M | -3.9M | |
Capital Expenditure | -9K | - | -41K | -26K | -46K | |
Other Investing Activities, Total | - | - | -7K | -5K | -38K | |
Cash from Investing | -9K | - | -48K | -31K | -84K | |
Long-Term Debt Repaid, Total | -38K | -39K | -38K | -11K | -22K | |
Total Debt Repaid | -38K | -39K | -38K | -11K | -22K | |
Issuance of Common Stock | 4.49M | 4.06M | 11.92M | 136K | 1.56M | |
Other Financing Activities, Total | - | - | 3.43M | - | 1.38M | |
Cash from Financing | 4.45M | 4.02M | 15.3M | 125K | 2.92M | |
Foreign Exchange Rate Adjustments | 29K | 28K | 84K | -128K | 9K | |
Net Change in Cash | 1.76M | 365K | 8.71M | -6.1M | -1.06M | |
Supplemental Items | ||||||
Levered Free Cash Flow | -968K | 2.99M | -7.41M | -6.25M | -720K | |
Unlevered Free Cash Flow | -943K | 2.99M | -7.4M | -6.24M | -720K | |
Change In Net Working Capital | -493K | -5.38M | 4.89M | 3.3M | -816K | |
Net Debt Issued / Repaid | -38K | -39K | -38K | -11K | -22K |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -115.71 | -85.4 | -55.3 | -40.06 | -34.16 | |
Return on Total Capital | -232.71 | 283.41 | -171.78 | -51.29 | -44.52 | |
Return On Equity % | -433.12 | 907.29 | -373.46 | -51.05 | -80.07 | |
Return on Common Equity | -433.12 | 907.29 | -368.83 | -48.73 | -89.55 | |
Margin Analysis | ||||||
Gross Profit Margin % | - | 37.5 | 61.73 | 82.34 | 87.71 | |
SG&A Margin | - | 37.3K | 3.16K | 267.57 | 102.4 | |
EBITDA Margin % | - | -58.56K | -3.79K | -243.49 | -27.6 | |
EBITA Margin % | - | -59.06K | -3.82K | -244.86 | -27.85 | |
EBIT Margin % | - | -59.06K | -3.82K | -244.86 | -27.85 | |
Income From Continuing Operations Margin % | - | -124K | -5.15K | -151.97 | -31.1 | |
Net Income Margin % | - | -124K | -5.13K | -147.09 | -34.41 | |
Net Avail. For Common Margin % | - | -124K | -5.13K | -147.09 | -34.41 | |
Normalized Net Income Margin | - | -77.76K | -3.2K | -90.07 | -21.77 | |
Levered Free Cash Flow Margin | - | 37.44K | -3.78K | -244.06 | -5.27 | |
Unlevered Free Cash Flow Margin | - | 37.44K | -3.78K | -244.01 | -5.27 | |
Asset Turnover | ||||||
Asset Turnover | - | 0 | 0.02 | 0.26 | 1.96 | |
Fixed Assets Turnover | - | 0.11 | 3.56 | 33.67 | 116.73 | |
Receivables Turnover (Average Receivables) | - | - | - | - | 87.83 | |
Inventory Turnover (Average Inventory) | - | - | 0.16 | 0.55 | 1.17 | |
Short Term Liquidity | ||||||
Current Ratio | 2.2 | 0.54 | 3.51 | 9.41 | 2.68 | |
Quick Ratio | 1.79 | 0.44 | 3.15 | 7.1 | 1.8 | |
Operating Cash Flow to Current Liabilities | -2.4 | -0.46 | -1.86 | -8.3 | -1.54 | |
Days Sales Outstanding (Average Receivables) | - | - | - | - | 4.16 | |
Days Outstanding Inventory (Average Inventory) | - | - | 2.29K | 662.57 | 312.83 | |
Average Days Payable Outstanding | - | - | 682.9 | 25.17 | 16.46 | |
Cash Conversion Cycle (Average Days) | - | - | - | - | 300.52 | |
Long Term Solvency | ||||||
Total Debt/Equity | 5.1 | -1.05 | 0.01 | 0.55 | 0.75 | |
Total Debt / Total Capital | 4.85 | -1.06 | 0.01 | 0.54 | 0.75 | |
LT Debt/Equity | 2.69 | -0.03 | - | 0.32 | 0.25 | |
Long-Term Debt / Total Capital | 2.56 | -0.03 | - | 0.32 | 0.25 | |
Total Liabilities / Total Assets | 45.27 | 183.23 | 28.34 | 10.77 | 36.8 | |
EBIT / Interest Expense | -75.02 | - | -575.38 | -3.13K | - | |
EBITDA / Interest Expense | -74.45 | - | -572.08 | -3.12K | - | |
(EBITDA - Capex) / Interest Expense | -74.68 | - | -575.23 | -3.13K | - | |
Total Debt / EBITDA | -0.02 | -0.01 | -0 | -0.01 | -0.01 | |
Net Debt / EBITDA | 0.64 | 0.49 | 1.49 | 0.79 | 1.02 | |
Total Debt / (EBITDA - Capex) | -0.02 | -0.01 | -0 | -0.01 | -0.01 | |
Net Debt / (EBITDA - Capex) | 0.64 | 0.49 | 1.48 | 0.79 | 1.01 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | - | - | 2.35K | 1.21K | 433.68 | |
Gross Profit, 1 Yr. Growth % | - | - | 3.93K | 1.64K | 468.49 | |
EBITDA, 1 Yr. Growth % | - | 57.32 | 58.74 | -16.22 | -39.5 | |
EBITA, 1 Yr. Growth % | 50.14 | 57.45 | 58.31 | -16.23 | -39.31 | |
EBIT, 1 Yr. Growth % | 50.14 | 57.45 | 58.31 | -16.23 | -39.31 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 63.21 | 198.44 | 1.39 | -61.46 | 9.23 | |
Net Income, 1 Yr. Growth % | 63.21 | 198.44 | 0.94 | -62.54 | 24.87 | |
Normalized Net Income, 1 Yr. Growth % | 63.21 | 198.44 | 0.68 | -63.2 | 28.99 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 14.25 | 122.23 | -27.16 | -66.21 | 20.95 | |
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | 301.61 | |
Inventory, 1 Yr. Growth % | - | - | 18.6 | 121.76 | 54.46 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 3.07K | -41.05 | -3.57 | 81.48 | 38.78 | |
Total Assets, 1 Yr. Growth % | 291.21 | 67.85 | 190.15 | -44.52 | -0.52 | |
Tangible Book Value, 1 Yr. Growth % | 1.01K | -355.27 | -351.04 | -29.39 | -35.83 | |
Common Equity, 1 Yr. Growth % | 1.01K | -355.27 | -351.04 | -29.39 | -35.83 | |
Cash From Operations, 1 Yr. Growth % | 74.23 | 35.8 | 79.79 | -8.48 | -35.65 | |
Capital Expenditures, 1 Yr. Growth % | 75 | - | - | -36.59 | 76.92 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -409.51 | -284.93 | -15.68 | -88.47 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -417.72 | -284.5 | -15.61 | -88.47 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | - | - | 1.69K | 734.74 | |
Gross Profit, 2 Yr. CAGR % | - | - | - | 2.55K | 894.95 | |
EBITDA, 2 Yr. CAGR % | - | - | 58.03 | 15.33 | -28.8 | |
EBITA, 2 Yr. CAGR % | - | 53.75 | 57.88 | 15.16 | -28.7 | |
EBIT, 2 Yr. CAGR % | - | 53.75 | 57.88 | 15.16 | -28.7 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 120.7 | 73.95 | -37.49 | -35.12 | |
Net Income, 2 Yr. CAGR % | - | 120.7 | 73.57 | -38.5 | -31.6 | |
Normalized Net Income, 2 Yr. CAGR % | - | 120.7 | 73.34 | -39.13 | -31.1 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 59.34 | 27.23 | -50.39 | -36.07 | |
Accounts Receivable, 2 Yr. CAGR % | - | - | - | 456.78 | - | |
Inventory, 2 Yr. CAGR % | - | - | - | 62.18 | 85.08 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 332.05 | -24.61 | 32.29 | 58.7 | |
Total Assets, 2 Yr. CAGR % | - | 156.26 | 120.69 | 26.87 | -25.71 | |
Tangible Book Value, 2 Yr. CAGR % | - | 432.93 | 153.15 | 33.14 | -32.69 | |
Common Equity, 2 Yr. CAGR % | - | 432.93 | 153.15 | 33.14 | -32.69 | |
Cash From Operations, 2 Yr. CAGR % | - | 53.82 | 56.26 | 28.28 | -23.26 | |
Capital Expenditures, 2 Yr. CAGR % | - | - | 113.44 | - | 5.92 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 176.69 | 24.86 | -68.83 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 180.19 | 24.77 | -68.81 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | - | 1.1K | |
Gross Profit, 3 Yr. CAGR % | - | - | - | - | 1.49K | |
EBITDA, 3 Yr. CAGR % | - | - | - | 27.9 | -6.99 | |
EBITA, 3 Yr. CAGR % | - | - | 55.25 | 27.81 | -6.98 | |
EBIT, 3 Yr. CAGR % | - | - | 55.25 | 27.81 | -6.98 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 70.29 | 5.26 | -24.71 | |
Net Income, 3 Yr. CAGR % | - | - | 70.04 | 4.12 | -22.13 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 69.89 | 3.41 | -21.81 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 22.74 | -18.22 | -33.23 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | - | 399.33 | |
Inventory, 3 Yr. CAGR % | - | - | - | - | 59.57 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 162.07 | 1.04 | 34.42 | |
Total Assets, 3 Yr. CAGR % | - | - | 167.09 | 39.28 | 16.99 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 314.66 | 65.4 | 4.39 | |
Common Equity, 3 Yr. CAGR % | - | - | 314.66 | 65.4 | 4.39 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 62.03 | 30.74 | 1.92 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 99.77 | 42.42 | - | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 86.19 | -43.57 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 87.81 | -43.59 | |
Compound Annual Growth Rate Over Five Years | ||||||
EBITA, 5 Yr. CAGR % | - | - | - | - | 13.73 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 13.73 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 15.76 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 18.13 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 18.41 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | -5.45 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 114.43 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 60.09 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 100.38 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 100.38 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 20.16 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 54.99 |